Preview

Медицинский алфавит

Расширенный поиск

Переходный период эстроген-гестагенной гормональной терапии

https://doi.org/10.33667/2078-5631-2019-3-25(400)-6-10

Полный текст:

Аннотация

Комбинированная гормональная контрацепция является эффективным методом предохранения от беременности и вместе с тем обладает рядом терапевтических эффектов. Потребность в контрацепции сохраняется вплоть до окончательного прекращения менструальной функции, но в старшем фертильном возрасте подбор гормонального средства становится непростой задачей. За предшествовавшие годы у женщины накапливаются факторы, которые могут осложнить применение гормональных препаратов, и, с другой стороны, в переходном периоде жизни возникают новые проблемы, разрешить которые способны комбинированные противозачаточные средства. Не менее актуальной темой становится вопрос о прекращении приема комбинированных гормональных контрацептивов и инициации менопаузальной гормональной терапии. Все перечисленные аспекты использования гормональных препаратов требуют глубокого осмысления для адекватного ведения женщин, вступающих в завершающую фазу репродуктивной жизни.

Об авторе

И. В. Кузнецова
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия

д. м. н., проф. кафедры акушерства и гинекологии № 1, Институт клинической медицины

г. Москва



Список литературы

1. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat. 2010; 23: 1–44.

2. Lader D. Contraception and sexual health, 2008–9. London (UK): Office for National Statistics; 2009. Available: www.ons.gov.uk/ons/rel/lifestyles/contraception-and-sexual-health/2008–09/index.html.

3. Black A, Yang Q, Wu Wen S, et al. Contraceptive use among Canadian women of reproductive age: results of a national survey. J Obstet Gynaecol Can. 2009; 31: 627–640.

4. United Nations, Department of Economic and Social Affairs, Population Division (2015). Trends in Contraceptive Use Worldwide 2015 (ST/ ESA/SER. A/349). Available at www.un.org/en/development/desa/population/publications/pdffamily/trendscontraceptiveuse2015report.pdf.

5. Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs and World Health Organization. Family planning: a global handbook for providers. Geneva (Switzerland): World Health Organization; 2011.

6. Trussell J, Guthrie K. Choosing a contraceptive: efficacy, safety, and personal considerations. In: Hatcher RA, Trussell J, Nelson AL, et al. editors. Contraceptive technology. 20th ed. Valley Stream (NY): Ardent Media Inc.; 2011: 45–74.

7. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257–2266.

8. Chakhtoura Z, Canonico M, Gompel A, et al. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011; 96: 1169–1174.

9. Chakhtoura Z, Canonico M, Gompel A, et al. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009; 40: 1059–1062.

10. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism: consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–122.

11. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen C, Rosendaal F. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case–control study. BMJ 2009; 339: b2921.

12. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.

13. Dinger J, Assmann A, Mohner S, et al. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010; 36: 123–129.

14. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FN, Stijen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347: f5298.

15. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018; 141(3): 287–294.

16. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011; 117: 777–787.

17. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009; 113: 1104–1116.

18. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013; 11: 41–47.

19. ACOG practice bulletin № 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115 (1): 206–218.

20. Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014; 5: 201–13.

21. Fait T, Buryak D, Cirstoiu M–M, Luczai E, Janczura R. Needs and prefereces of women users of oral contraceptives in selected countries in Central and Eastern Europe. Drugs in Context. 2018; 7: 21510.

22. Petto J, Vasques LM, Pinheiro RL, et al. Comparison of postprandial lipemia between women who are on oral contraceptive methods and those who are not. Arq Bras Cardiol. 2014; 103 (3): 245–250.

23. Dos Santos CAN, Petto J, Diogo DP, Seixas CR, de Souza LH, Ladeia AMT. Elevation of oxidized lipoprotein of low density in users of combined oral contraceptives. Arq Bras Cardiol. 2018; 111 (6): 764–770.

24. Sørensen CJ, Pedersen OB, Petersen MS, et al. Combined oral contraception and obesity are strong predictors of low-grade inflammation in healthy individuals: results from the Danish Blood Donor Study (DBDS). PLoS One. 2014; 9 (2): e88196.

25. Petto J, Pereira LS, Santos AC, Giesta BA, Melo TA, Ladeia AM. Inflamação subclínica em mulheres que utilizam contraceptivo oral. Rev Bras Cardiol. 2013; 26 (6): 465–471.

26. Harvey RE, Hart EC, Charkoudian N, Curry TB, Carter JR, Fu Q. Oral contraceptive use, muscle sympathetic nerve activity, and systemic hemodynamics in young women. Hypertension. 2015; 66 (3): 590–597.

27. Corrêa DA. Uso de contraceptivos orais entre mulheres de 18 a 49 anos: inquérito populacional telefônico. [Dissertação]. Belo Horizonte. Escola de Enfermagem da UFMG; 2012.

28. Nachtigall L, Naftolin F, Keefe DL. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2018; 378: 1265.

29. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 127 (2): 442–451.

30. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013; 31: 4188–4198.

31. Havrilesky LJ, Gierisch JM, Moorman PG, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep). 2013; 212: 514.

32. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22 (11): 1931–1943.

33. Veljković M, Veljković S. The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl. 2010; 63 (9–10): 657–661.

34. Caruso S, Iraci M, Cianci S, et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest / 30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 8: 923–931.

35. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010; 82 (3): 221–229.

36. Allali F, Mansouri L, Abourazzak F, et al. The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Women’s Health. 2009; 9: 31.

37. Hannaford PC, Iversen L, Mactariane TV, et al. Mortality among contraceptive pill users: cohort evidence from Royal college of general practitioners’ oral contraception study. BMJ 2010; 340: 927.

38. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 14: e4944.

39. Allen RH, Cwiak CA. Contraception for midlife women. Menopause 2016; 23 (1): 183–191.

40. Madden T, Secura GM, Nease RF, Politi MC, Peipert JF. The role of contraceptive attributes in women’s contraceptive decision making. Am J Obstet Gynecol. 2015; 213 (1): 46.e1–46.e6.

41. Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig. 2010; 30 (11): 749–763.

42. d’Arcangues CM, Ba-Thike K, Say L. Expanding contraceptive choice in the developing world: lessons from the Lao People’s Republic and the Republic of Zambia. Eur J Contracept Reprod Health Care. 2013; 18: 421–34.

43. Blanc A, Tsui AO, Croft TN, Trevitt JL. Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health. 2009; 35 (2): 63–71.


Для цитирования:


Кузнецова И.В. Переходный период эстроген-гестагенной гормональной терапии. Медицинский алфавит. 2019;3(25):6-10. https://doi.org/10.33667/2078-5631-2019-3-25(400)-6-10

For citation:


Kuznetsova I.V. Transition period of estrogen-progestogen hormone therapy. Medical alphabet. 2019;3(25):6-10. (In Russ.) https://doi.org/10.33667/2078-5631-2019-3-25(400)-6-10

Просмотров: 91


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)